Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Cboe BZX  -  07:53 2022-12-09 am EST
188.66 USD   +2.14%
04:33aParainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Treatment Domain
AQ
12/08S&P snaps losing streak on jobless claims rise
RE
12/08S&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast

08/09/2022 | 07:36am EST
FILE PHOTO: FILE PHOTO: Vials and medical syringe are seen in front of Novavax logo in this illustration

(Reuters) - U.S. vaccine maker Novavax slumped nearly 31% on Tuesday as falling demand for its COVID-19 shot from low- and middle-income nations led the company to cut its annual revenue expectation by half.

Demand for its vaccine is also waning in the United States, where it was authorized for use among adults last month and was expected to be preferred by the skeptics of messenger RNA-based shots from Moderna Inc and Pfizer Inc.

But only 7,381 Novavax vaccine doses have been administered so far in the country, with Chief Executive Stanley Erck saying that its late launch could have hampered demand.

The company now expects 2022 revenue between $2 billion and $2.3 billion, compared with its prior forecast of $4 billion to $5 billion when it was hoping to benefit from the demand for its shots as part of the COVAX vaccine sharing program.

The forecast cut also dashes any hope of Novavax being able to garner a share of the market for the two-dose initial vaccination program, said Cowen analyst George Yordanov.

"We completely share and understand investors' frustration with management's execution and lack of accurate near-term guidance," he said in a note.

Analysts, however, expect the company to capture a small but meaningful share of a fast-developing market for COVID re-vaccinations.

It could still be a 'viable COVID vaccine player in the future $5-10 billion market' as it has shown comparable/better clinical profile vs mRNA vaccines, Jefferies analyst Roger Song said in a note.

Novavax shares were trading lower at $39.30 before the bell. Rival Moderna Inc was also down about 3%. Earlier this month, it said gains from orders for new booster shots were offset by unallocated vaccines under the COVAX program.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 3.18% 184.7 Delayed Quote.-29.52%
NOVAVAX, INC. 0.58% 17.32 Delayed Quote.-87.89%
PFIZER, INC. 3.07% 51.78 Delayed Quote.-14.92%
All news about MODERNA, INC.
04:33aParainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to En..
AQ
12/08S&P snaps losing streak on jobless claims rise
RE
12/08S&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
12/08S&P 500 snaps losing streak on jobless claims rise
RE
12/08FDA Authorizes Pfizer-BioNTech, Moderna COVID-19 Shots for Children as Young as Six Mon..
MT
12/08S&P 500 rebounds as investors take rate hike cues from jobless claims rise
RE
12/08FDA approves Moderna, Pfizer bivalent COVID-19 vaccines for youngest kids
AQ
12/08S&P 500 rebounds on tech boost; weekly jobless claims rise
RE
12/08Moderna Gets US Emergency Use Authorization for Bivalent Omicron Jab for Infants, Young..
MT
12/08FDA clears updated COVID-19 vaccines for kids under age 5
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,56x
Yield 2022 -
Capitalization 70 958 M 70 958 M -
EV / Sales 2022 3,09x
EV / Sales 2023 6,53x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 184,70 $
Average target price 211,25 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-29.52%70 958
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.36.41%29 282
SEAGEN INC.-18.99%23 253
CELLTRION, INC.-10.86%18 466